Brief: Allarity’S Early Phase 2 Stenoparib Data Indicates Clinical Benefit In Women With Advanced Ovarian Cancer Selected With Drp® Companion Diagnostic
05/12/2023 12:33
Dec 5 (Reuters) - Allarity Therapeutics Inc ALLR.O :
* ALLARITY’S EARLY PHASE 2 STENOPARIB DATA INDICATES
CLINICAL
BENEFIT IN WOMEN WITH ADVANCED OVARIAN CANCER SELECTED WITH DRP®
COMPANION DIAGNOSTIC
* ALLARITY THERAPEUTICS: OF 5 EVALUABLE PATIENTS INCLUDED IN
INITIAL ANALYSIS, 1 PATIENT EXPERIENCED COMPLETE RESPONSE, OTHER
4 SHOWED STABLE DISEASE
Source text for Eikon: ID:nGNXbCprpl
Further company coverage: ALLR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic